Comparative Pharmacology
Head-to-head clinical analysis: APIDRA versus MERILOG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APIDRA versus MERILOG.
APIDRA vs MERILOG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin glulisine is a rapid-acting insulin analog that lowers blood glucose by binding to and activating insulin receptors on cells, facilitating glucose uptake into muscle and adipose tissue, and inhibiting hepatic glucose production.
Merilog is a recombinant human insulin analog that lowers blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. It also inhibits lipolysis and proteolysis, and enhances protein synthesis.
Subcutaneous injection 0.2-0.4 units/kg once daily or divided twice daily, or as part of basal-bolus regimen with 50-70% of total daily insulin as prandial insulin given within 15 minutes before or within 20 minutes after starting a meal.
10 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 30 minutes. This short half-life allows for flexible dosing and rapid clearance, but necessitates multiple daily injections or continuous subcutaneous insulin infusion.
The terminal elimination half-life is approximately 18 hours, allowing for once-daily dosing in most patients. In renal impairment (CrCl <30 mL/min), half-life is prolonged to >40 hours, requiring dose adjustment.
Primarily renal; ~60% of a dose is excreted as metabolites and unchanged drug in urine. Fecal elimination is minimal (<10%).
MERILOG is primarily excreted renally as unchanged drug (85%) and as minor metabolites (10%). Fecal excretion accounts for less than 5%.
Category C
Category C
Insulin
Insulin